New View of Gliomas

June 5, 2018
Ovidiu Andronesi
Ovidiu Andronesi

HMS News article from on a recent Nature Communications paper from the lab of Ovidiu Andronesi, interested in developing new imaging methods for an often deadly form of brain tumors known as gliomas.

Here his team used magnetic resonance spectroscopy (MRS) imaging to study tumors in patients with mutations in the IDH enzyme, who respond better to chemo and radiation therapy and tend to live three to five times longer than patients whose tumors do not carry this mutation. They found that an IDH1 inhibitor compound currently in Phase I clinical trials reduced levels of 2HG, a tumor-associated metabolite in these glioma patients—increasing hope for its exploration in larger group trials, with longer follow-up studies.

Said Andronesi on the importance of this research: “There is a desperate need for progress in glioma treatment, and IDH mutations, which occur commonly in these tumors, offer a pathway for targeted therapy,”

Read more here >>

Glioma research image
Magnetic resonance spectroscopy in patients with IDH mutation gliomas shows significant reduction in the tumor-associated metabolite 2HG after treatment with an IDH1 inhibitor. Image courtesy of Ovidiu Andronesi.
See also: In the News